(107 days)
Not Found
No
The summary describes a passive medical device (a pacing lead) and does not mention any computational or analytical capabilities that would involve AI/ML.
Yes
The device is a pacing lead, which is a component of an implantable medical device designed to permanently pace and sense the heart, thereby treating cardiac rhythm disorders.
No
The device is described as a "transvenous, active-fixation endocardial lead" for "permanent pacing and sensing," used in conjunction with "implantable pulse generators." Its function is pacing (delivering electrical impulses to the heart) and sensing (detecting the heart's electrical activity), not diagnosing a medical condition.
No
The device description clearly states it is a transvenous, bipolar, active fixation, endocardial pacing lead, which is a physical hardware device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for "permanent pacing and sensing" within the human body. This is a therapeutic and diagnostic function performed in vivo (within a living organism), not in vitro (outside of a living organism, typically on biological samples).
- Device Description: The device is described as a "transvenous, bipolar, active fixation, endocardial pacing lead." This is a medical device designed to be implanted within the heart.
- Lack of IVD Characteristics: The description does not mention any analysis of biological samples (like blood, urine, tissue), diagnostic tests performed on these samples, or any function related to diagnosing a disease or condition based on in vitro analysis.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device does not fit that description.
N/A
Intended Use / Indications for Use
The BIOTRONIK RETROX RX 53/60-BP and RETROX RX 45/53-JBP transvenous, active-fixation endocardial leads are indicated for permanent pacing and sensing. Active-fixation pacing leads with a bipolar (BP) IS-1 connector configuration are designed for use in conjunction with implantable pulse generators. The leads may be used with single- or dual-chamber pacing systems.
RETROX RX-BP and RX-JBP leads differ in the shape of the distal portion of the lead. The RX-BP models are intended for placement in the ventricle or atrium and have straight distal ends. The RX-IBP models have a pre-formed J-shaped distal end to facilitate lead placement in the right attial appendage.
Product codes
74 DTB
Device Description
BIOTRONIK's Retrox leads are transvenous, bipolar, active fixation, endocardial pacing leads. The Retrox lead being introduced in this 510(k) notification is identical to the Retrox lead already cleared for distribution with the exception that the material used to construct the fixation helix has changed to Elgiloy. Currently, the fixation helix in the Retrox is manufactured with an alloy containing 70% platinum/30% iridium.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
ventricle or atrium, right atrial appendage
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.3680 Cardiovascular permanent or temporary pacemaker electrode.
(a)
Temporary pacemaker electrode —(1)Identification. A temporary pacemaker electrode is a device consisting of flexible insulated electrical conductors with one end connected to anexternal pacemaker pulse generator and the other end applied to the heart. The device is used to transmit a pacing electrical stimulus from the pulse generator to the heart and/or to transmit the electrical signal of the heart to the pulse generator.(2)
Classification. Class II (performance standards).(b)
Permanent pacemaker electrode —(1)Identification. A permanent pacemaker electrode is a device consisting of flexible insulated electrical conductors with one end connected to an implantable pacemaker pulse generator and the other end applied to the heart. The device is used to transmit a pacing electrical stimulus from the pulse generator to the heart and/or to transmit the electrical signal of the heart to the pulse generator.(2)
Classification. Class III (premarket approval).(c)
Date PMA or notice of completion of PDP is required. A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before October 4, 2012, for any permanent pacemaker electrode device that was in commercial distribution before May 28, 1976, or that has, on or before October 4, 2012, been found to be substantially equivalent to any permanent pacemaker electrode device that was in commercial distribution before May 28, 1976. Any other pacemaker repair or replacement material device shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
0
Retrox Active Fixation Endocardial Lead
BIOTRONIK, Inc.
510(K) SUMMARY
Name and Address of Sponsor:
6024 Jean Road
Lake Oswego, OR 97035
| Establishment Registration Number: | 1028232 |
|---|---|
| Device Name: | Proprietary Names: RX-45-JBP, RX 53-BP, RX 53-BP, and RX 60-BP Classification: Class III (21 CFR 870.3680(b)) Classification Name: Cardiovascular permanent pacemaker electrode |
| Date Prepared: | May 17, 1999 |
General Description and Predicate Devices:
BIOTRONIK's Retrox leads are transvenous, bipolar, active fixation, endocardial pacing leads. The predicate device for the Retrox Endocardial Lead with Elgiloy Active-Fixation is the Retrox Active-Fixation Endocardial Lead. BIOTRONIK obtained clearance to commercially distribute the Retrox Active-Fixation Endocardial Lead on July 22, 1998 after determination of substantial equivalence under 510(k) #K981083. The Retrox lead being introduced in this 510(k) notification is identical to the Retrox lead already cleared for distribution with the exception that the material used to construct the fixation helix has changed to Elgiloy. Currently, the fixation helix in the Retrox is manufactured with an alloy containing 70% platinum/30% iridium.
With regard to the Retrox lead's new active fixation material, the VascoTwist 9/60 series of endocardial leads (#K920662, dated 11/24/93) is the predicate device to which the Retrox lead with Elgiloy is substantially equivalent.
Indications for Use:
The BIOTRONIK RETROX RX 53/60-BP and RETROX RX 45/53-JBP transvenous, active-fixation endocardial leads are indicated for permanent pacing and sensing. Active-fixation pacing leads with a bipolar (BP) IS-1 connector configuration are designed for use in conjunction with implantable pulse generators. The leads may be used with single- or dual-chamber pacing systems.
RETROX RX-BP and RX-JBP leads differ in the shape of the distal portion of the lead. The RX-BP models are intended for placement in the ventricle or atrium and have straight distal ends. The RX-IBP models have a pre-formed J-shaped distal end to facilitate lead placement in the right attial appendage.
Name and Address of Manufacturing Site: BIOTRONIK GmbH & Co.(reg. no. 7010992) Woermannkehre 1, Berlin, Germany 011-49-30-689-05-304
Sponsor Contact Person and Phone Number: Jon Brumbaugh, Regulatory Affairs Manager Phone (888) 345-0374 Fax (503) 635-9936
1
Image /page/1/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized caduceus, a symbol often associated with medicine and healthcare, with three intertwined snakes around a staff. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the caduceus.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUN 3 1000
Mr. Jon Brumbaugh Biotronik, Inc. 6024 Jean Road Lake Oswego, OR 97035
Re: K990483 Trade Name: Retrox Active-Fixation Endocardial Pacing Leads Models RX-BP amd RX-JBP Regulatory Class: III Product Code: 74 DTB Dated: May 24, 1999 Received: May 25, 1999
Dear Mr. Brumbaugh:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments. You may, therefore, market the device, subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act (Act). The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, and labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, FDA will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not
2
Page 2 - Mr. Jon Brumbaugh
affect any obligation you might have under section 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.
On August 16, 1993 the Final Rule for Device Tracking was published in the Federal Register, pages 4342-43455 (copy enclosed). Be advised that under Section 519(e) of the Act as amended by the Safe Medical Devices Act of 1990, FDA has identified the above device as a device which requires tracking. Because the device is subject to tracking, you are required to adopt a method of tracking that follows the devices through the distribution chain and then identifies and follows the patients who receive them. The specific requirements of the regulation are found in 21 CFR 821 as described in the August 16, 1993 Federal Register beginning on page 43447.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4586. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please not the requlation entitled, " Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities
3
Page 3 - Mr. Jon Brumbaugh
under the Act, may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Thomas J. Callahon
Thomas J. CallaWan, Ph.D Director Division of Cardiovascular, Respiratory and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
4
Indications for Use:
.. "
The BIOTRONIK RETROX RX 53/60-BP and RETROX RX 45/53-JBP transvenous, active-fixation endocardial leads are indicated for permanent pacing and sensing. Active-fixation pacing leads with a bipolar (BP) IS-1 connector configuration are designed for use in conjunction with implantable pulse generators. The leads may be used with single- or dual-chamber pacing systems.
RETROX RX-BP and RX-JBP leads differ in the shape of the distal portion of the RX-BP models are intended for placement in the ventricle or atrium and have straight distal ends. The RX-JBP models have a pre-formed J-shaped distal end to facilitate lead placement in the right atrial appendage.
sception
Obi-tyl. Al. for TC.
(Division Sian-O Division o and Net 510(k) Num